View in EDS

Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.

Saved in:
Bibliographic Details
Title: Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
Authors: Feig SA; University of California School of Medicine, Los Angeles., Krailo MD, Harris RE, Baum E, Holcenberg JS, Kaizer H, Steinherz L, Pendergrass TW, Saunders EF, Warkentin PL, et. al.
Source: Medical and pediatric oncology [Med Pediatr Oncol] 1992; Vol. 20 (2), pp. 124-9.
Publication Type: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7506654 Publication Model: Print Cited Medium: Print ISSN: 0098-1532 (Print) Linking ISSN: 00981532 NLM ISO Abbreviation: Med Pediatr Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 1734217
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Feig+SA%22">Feig SA</searchLink>; University of California School of Medicine, Los Angeles.<br /><searchLink fieldCode="AU" term="%22Krailo+MD%22">Krailo MD</searchLink><br /><searchLink fieldCode="AU" term="%22Harris+RE%22">Harris RE</searchLink><br /><searchLink fieldCode="AU" term="%22Baum+E%22">Baum E</searchLink><br /><searchLink fieldCode="AU" term="%22Holcenberg+JS%22">Holcenberg JS</searchLink><br /><searchLink fieldCode="AU" term="%22Kaizer+H%22">Kaizer H</searchLink><br /><searchLink fieldCode="AU" term="%22Steinherz+L%22">Steinherz L</searchLink><br /><searchLink fieldCode="AU" term="%22Pendergrass+TW%22">Pendergrass TW</searchLink><br /><searchLink fieldCode="AU" term="%22Saunders+EF%22">Saunders EF</searchLink><br /><searchLink fieldCode="AU" term="%22Warkentin+PL%22">Warkentin PL</searchLink><br />et. al.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227506654%22">Medical and pediatric oncology</searchLink> [Med Pediatr Oncol] 1992; Vol. 20 (2), pp. 124-9.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley-Liss%22">Wiley-Liss </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7506654 <i>Publication Model: </i>Print <i>Cited Medium: </i>Print <i>ISSN: </i>0098-1532 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200981532%22">00981532 </searchLink><i>NLM ISO Abbreviation: </i>Med Pediatr Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=1734217
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1002/mpo.2950200207
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 124
    Titles:
      – TitleFull: Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: a report from the Childrens Cancer Study Group.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Feig SA
      – PersonEntity:
          Name:
            NameFull: Krailo MD
      – PersonEntity:
          Name:
            NameFull: Harris RE
      – PersonEntity:
          Name:
            NameFull: Baum E
      – PersonEntity:
          Name:
            NameFull: Holcenberg JS
      – PersonEntity:
          Name:
            NameFull: Kaizer H
      – PersonEntity:
          Name:
            NameFull: Steinherz L
      – PersonEntity:
          Name:
            NameFull: Pendergrass TW
      – PersonEntity:
          Name:
            NameFull: Saunders EF
      – PersonEntity:
          Name:
            NameFull: Warkentin PL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 1992
              Type: published
              Y: 1992
          Identifiers:
            – Type: issn-print
              Value: 0098-1532
          Numbering:
            – Type: volume
              Value: 20
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Medical and pediatric oncology
              Type: main
ResultId 1